What Eroxim Treats: Main Uses and Benefits

Eroxim (Sildenafil) is applied across two distinct therapeutic domains, supporting symptomatic relief in areas where targeted assistance is required. The medication is relevant in contexts where additional management of discomfort is appropriate. It is generally used in situations where patients experience symptoms that interfere with daily functioning.

Therapeutic Support for Key Symptom Domains

The medication is commonly used to help manage symptoms associated with Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). This means it is commonly used to help manage groups of symptoms associated with insufficient erection quality and difficulty sustaining an erection, as well as symptoms of increased physiological strain in the lungs, such as tiredness during activity and shortness of breath.

This approach contributes to easing the overall symptom load and helps patients cope more steadily with difficult episodes by providing supportive relief when symptoms interfere with routine activities. The medication helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability necessary for routine activities.

Quick Fact: Relief for Key Symptom Domains
Symptom Domain 1: Difficulty achieving or sustaining an erection adequate for sexual intercourse (Erectile Dysfunction).
Symptom Domain 2: Physical strain, shortness of breath, and tiredness during activity (Pulmonary Arterial Hypertension).

Regulatory References

1. NIH MedlinePlus overview

Eroxim is approved for adult men seeking treatment for Erectile Dysfunction (ED) and for adults and children aged 1 year and older for the Pulmonary Arterial Hypertension (PAH) indication. Use is strictly contraindicated for several populations, as defined in regulatory labeling.

Absolute Contraindications

• Patients taking any form of organic nitrates or nitric oxide donors.
• Patients concurrently using the guanylate cyclase stimulator, riociguat.
• Individuals with known hypersensitivity to the medicine or its components.
• Patients with severe hepatic impairment (severe liver function problems).
• Patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION).

Age and Sex Restrictions Use is not indicated for women for the ED formulation, and is not recommended during pregnancy or lactation. The medicine is contraindicated for the ED indication in children. For the PAH indication, use is established for children aged one year and older under restrictive guidelines.

Conditional Use Special consideration or caution is required for patients with a recent history of stroke or myocardial infarction, severe hypotension (low blood pressure), severe renal impairment (severe kidney problems), or conditions that increase the risk of priapism (e.g., sickle cell anemia).

Interactions with other medicines and products

The interaction profile for Eroxim (Sildenafil) is defined by specific pharmacokinetic and pharmacodynamic constraints established in official government regulatory documents.

Absolute Contraindications and Restrictions

Co-administration of Eroxim is strictly contraindicated with all forms of Organic Nitrates and the soluble guanylate cyclase stimulator Riociguat. These prohibitions are mandatory due to the significant risk of symptomatic, severe hypotension resulting from the potentiation of their blood pressure-lowering effects. Co-administration with other PDE5 inhibitors is also not recommended.

Metabolic and Exposure-Altering Interactions

Sildenafil's clearance is managed primarily through the CYP3A4 enzyme pathway. Strong inhibitors of this enzyme, such as Ritonavir, dramatically reduce Sildenafil's breakdown, officially documented to increase systemic exposure (AUC) up to eleven-fold. This significant exposure increase requires a mandatory administration restriction for certain indications: the Sildenafil dose must not exceed 25 mg within a 48-hour period when taken concurrently with Ritonavir. Moderate CYP3A4 inhibitors, including Erythromycin, also cause documented increases in plasma concentrations.

Pharmacodynamic and Substance Interactions

An additive blood pressure-lowering effect may occur when Eroxim is taken with Alpha-blockers, with regulatory warnings noting that the greatest risk of symptomatic hypotension is typically within four hours of dosing. Grapefruit juice is documented to potentially increase the medicine's plasma levels. Furthermore, individuals with severe hepatic or renal impairment may experience inherently higher plasma levels, a factor that can amplify the clinical relevance of other clearance-reducing drug interactions.

Inhibiting the PDE5 Enzyme to Amplify Signals

This mechanism initiates with the drug acting as a selective inhibitor of the enzyme phosphodiesterase type 5 (PDE5), which is responsible for breaking down the key signaling molecule cGMP in certain cells. By blocking this enzyme, the drug prevents the natural termination of the signal, thus increasing the duration and magnitude of the cGMP signal initiated by naturally released nitric oxide (NO).

---

The NO-cGMP Pathway and Smooth Muscle Tone

The resulting buildup of cGMP inside vascular smooth muscle cells is central to the drug's effect, as it activates a molecular cascade that leads to a reduction in muscle tension. This targeted modulation of the NO-cGMP pathway is a key step in altering the activity of the system that controls localized smooth muscle tone.

---

Physiological Outcome: Localized Vasodilation and Increased Blood Flow

The final physiological consequence of this enzyme inhibition and signaling molecule accumulation is vasodilation—the relaxation and widening of specific blood vessels. This adjustment in peripheral vascular dynamics results in an increase in blood flow to the targeted tissues, which is the direct effect of the drug's mechanism.

How Eroxim is Used: Official Administration Guidelines

Eroxim (Sildenafil) use is governed by distinct protocols depending on the condition being managed. The medicine is primarily administered via the oral route (tablets or suspension), with an intravenous (IV) injection form available for patients with Pulmonary Arterial Hypertension (PAH) who are temporarily unable to tolerate oral intake.

Dosing and Frequency by Use

Condition	Starting Dose (Oral)	Maximum Frequency	Dosing Schedule	Time Constraints
Erectile Dysfunction (ED)	50 mg	Once per day	As-needed (On-Demand)	Take 30 minutes to 4 hours before activity.
Pulmonary Arterial Hypertension (PAH)	20 mg	Three times per day (TID)	Scheduled Maintenance	Doses are taken approximately 4–6 hours apart.

General Administration Conditions

For ED use, the oral tablets can be taken with or without food. However, it is observed that ingestion with a high-fat meal may lead to a delayed onset of activity. The maximum single dose for ED is 100 mg.

Population-Specific Adjustments

Guidelines suggest considering a lower 25 mg starting dose for ED use in specific patient populations, including older adults (aged 65 years and over) and those with severe renal impairment (creatinine clearance <30 mL/ min) or hepatic impairment. A 25 mg dose is also advised when initiating therapy in patients already stabilized on alpha-blocker therapy or when co-administering with strong CYP3 A4 inhibitors.

Research Evidence / Overview of Studies for Eroxim

This section outlines the research that has evaluated Eroxim for its main purpose, focusing on the study designs, the way outcomes were measured, and where the current evidence is limited. This information is based on the findings reported in the studies and should not be used as clinical advice or a prediction of personal outcomes.

Evidence for Use in Erectile Dysfunction (ED)

Research into Eroxim has primarily evaluated it in adult men with ED. The evidence base includes multiple Randomized Controlled Trials (RCTs), a design frequently used in research exploring how symptoms change over time. These studies monitored changes in sexual function over defined, short-term intervals, typically 12 weeks to 24 weeks.

Researchers used in research exploring how symptoms change over time the International Index of Erectile Function (IIEF-EF) domain score and the Sexual Encounter Profile (SEP) questions to gather patient-reported data. These tools are used in research contexts to assess patient-reported outcomes describing perceived discomfort and functional measures used in the study. The findings describe patterns observed in the studies where participants across different severity levels of ED were evaluated in these trials.

Comparing Eroxim Research Against Placebo and Other Treatments

The research structure includes studies designed to rule out a “placebo” effect and to provide context relative to other treatments. Some studies explored outcomes by comparing an Eroxim group against a non-active control group. Furthermore, one trial research explored a comparison against a specific oral prescription agent used in research.

These studies monitored patient-reported function over 24 weeks, and studies monitored the frequency of attempts to complete intercourse. The reported findings describe patterns observed in the studies between the investigational group and the comparator group, based on the metrics like IIEF-EF and SEP scores.

Key Gaps and Remaining Uncertainties in the Evidence

The current evidence is primarily derived from trials with limited follow-up durations of 12 or 24 weeks. Long-term outcomes are not fully established beyond this duration, and there is limited information for long-term outcomes regarding the persistence of the findings observed in the studies. Furthermore, comparative evidence is lacking against a full range of alternative treatments, and data for certain groups remain insufficient.

Common questions about Eroxim (FAQ)

Q: Why is Eroxim contraindicated with nitrates?

A: Official regulatory documents strictly prohibit taking Eroxim concurrently with any form of organic nitrates. This is due to the significant risk of severe, symptomatic, life-threatening low blood pressure (hypotension) resulting from the strong potentiation of the blood pressure-lowering effects. It is an absolute contraindication noted on the official label.

Q: How long does it take for Eroxim to start working?

A: Studies and official information indicate that the time to reach maximum concentration of the medication in the bloodstream—which correlates with the onset of activity—is typically between 30 and 120 minutes after taking it. Studies indicate the median time is approximately 60 minutes when the medicine is taken on an empty stomach, though individual results and onset time may vary.

Q: What patient groups need a lower starting dose of Eroxim?

A: Regulatory labeling suggests considering a lower starting dose for certain patient populations. These groups include older adults, individuals with severe kidney or liver impairment, and those who are also taking strong enzyme inhibitors (CYP3A4 inhibitors) or alpha-blockers. These adjustments are generally advised because these conditions may cause these patients to have higher concentrations of the medicine in their system.

Q: Does taking Eroxim with a fatty meal change the effects?

A: According to official product information, ingesting the tablet with a high-fat meal can affect how your body absorbs the medication. This reduction in the rate of absorption has been shown to potentially result in a delay in the onset of the medicine's activity.

Q: What is the recommended storage temperature for Eroxim?

A: Regulatory documents recommend storing the medicine at Controlled Room Temperature, ideally 25 C (77 F). The product information states that temperatures can safely fluctuate between 15 C to 30 C. The product must also be protected from moisture and kept in its original, tightly closed container.

Q: What other prescription drugs interact with Eroxim, besides Ritonavir?

A: Official labeling highlights several significant interactions beyond Ritonavir. Co-administration is strictly contraindicated with all forms of organic nitrates and the medication Riociguat. Official labeling notes that an additive blood pressure-lowering effect may occur when taken with alpha-blockers. Additionally, other enzyme inhibitors, such as Erythromycin and Cimetidine, are documented to potentially increase the concentration of the medicine in the body.

Q: How long does Eroxim stay in the body?

A: According to official pharmacokinetic studies, both sildenafil, the active substance, and its major breakdown product have an elimination half-life of approximately four hours. The half-life refers to the approximate time it takes for the amount of the drug in the body to decrease by half.

Q: What are the ingredients in Eroxim tablets, besides Sildenafil?

A: The tablets contain the active ingredient Sildenafil, and the remainder of the tablet is made up of inactive ingredients, also called excipients. Official documents list these excipients as including microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, lactose, and triacetin.

How to Store and Dispose of Eroxim?

Official regulatory guidelines define specific conditions to maintain the stability and integrity of Eroxim (Sildenafil).

Storage Component	Requirement
Temperature	Store at Controlled Room Temperature, ideally 25 C (77 F), with permitted fluctuations between 15 C to 30 C.
Protection	The product must be kept in its original container, kept tightly closed, and protected from moisture. Do not freeze.
Child Safety	The medicine must be stored out of the sight and reach of children and pets.

For disposal of unused or expired tablets, the preferred method is utilizing a community drug take-back program. Eroxim is not on the official list of medicines to be flushed down the toilet or sink. If a take-back option is unavailable, the product should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash.